Intismeran autogene a turning point for cancer vaccines
Intismeran autogene is fully personalised, as tissue from the resected tumour is sequenced to identify up to 34 mutations unique to that patient's cancer.
Therapy Area
Updated UK guidance for finerenone introduces new treatment for HF patients
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market
Evotec and Odyssey collaborate on AI-enabled R&D
Pfizer seeks label expansion for Litfulo after double Phase III NSV win
Novartis and Takeda drugs gain rare blood cancer routine use on NHS
Bayer’s heart failure drug bound for NHS on NICE recommendation
Women’s health attracted record equity in 2025 as companies share capital
